Abuse Resistant Opioid Laws and their upcoming impact on

New Post Public Reply Private Reply Replies (1) Message Board

Dec 20, 2012 at 8:40 AM

Abuse Resistant Opioid Laws and their upcoming impact on ELTP
If you look at the laws related to abuse resistant opioids and their cumulative effect from 1970-2012 (Present day) you realize passing the next wave of bills such as the STOPP ACT is just the next wave of laws coming.
http://bono.house.gov/news/documentprint.aspx...tID=303838
https://www.popvox.com/bills/us/112/hr6160

http://www.cdc.gov/homeandrecreationalsafety/...index.html
Timeline of Law Enactment
Over the past two decades, the number of states having one or more laws aimed at reducing prescription drug misuse, abuse, and overdose has increased. Lawmaking in this area has steadily accelerated along with growing awareness of prescription drug abuse.
1970s: A few states enacted laws requiring physical examinations of patients before prescribing and imposing prescription limits.

1980s: More states enacted physical examination and prescription limit laws, while a few states began to require identification when picking up prescriptions for controlled substances, and others enacted laws to prohibit doctor shopping.

1990s: Laws were passed in multiple categories, especially physical exam laws, which were enacted by an additional eight states.

2000s: Half of US states adopted tamper-resistant prescription form laws, which was prompted by the passage of federal tamper-resistant form legislation in 2007. During this same decade, a small number of states introduced pain clinic laws and laws that provided immunity or mitigation at sentencing for individuals obtaining medical assistance during an overdose.

AND with Government and Federal pressure placing an emphasis on curtailing the prescription abuse epidemic...it is only a matter of time before a few select Pharma companies will benefit from this pressure and mandates happening daily.
1) The White House has an agenda to curb the epidemic that is prescription drug abuse....
http://www.whitehouse.gov/sites/default/files...e_plan.pdf
Prescription drug abuse is the Nation’s fastest-growing drug problem. While there has been a marked decrease in the use of some illegal drugs like cocaine, data from the National Survey on Drug Use and Health (NSDUH) show that nearly one-third of people aged 12 and over who used drugs for the first time in 2009 began by using a prescription drug non-medically.

2) The House of Representatives recently passed a bill that gives additional funding to the FDA to offset drug shortages....
http://www.reuters.com/article/2012/05/30/us-...LQ20120530
The main purpose of the bill is to reauthorize fees from makers of drugs and devices that help speed FDA evaluation of new medical products. These so-called "user fees" could make up nearly half of the FDA's proposed $4.5 billion budget next year, according to a plan from President Barack Obama.
~~As we know Naltrexone is one of those drugs on various drug shortage lists!
http://www.ashp.org/DrugShortages/Current/bul...spx?id=873

3) The Supreme Court upheld the constitutionality of Obama's Health Care Plan....meaning that everyone will be required to have health care. This, though controversial, will unsure that less money will be spent on the poor and indigent population that uses a disproportionate amount of prescription related opioid abuse funds.
http://www.voanews.com/content/breaking-news-...64278.html

http://www.kentucky.com/2012/02/23/2081181/ho...aging.html
Measure backs use of tamper-resistant pills

A bill approved recently would encourage use of tamper-resistant pain medication in Kentucky as a way to combat the state's crippling level of prescription-drug abuse.

The House Health and Welfare committee voted 13-0 to approve House Bill 377.

Elite Pharmaceuticals Inc (ELTP) Stock Research Links

ELTP Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Invasive Procedures Don't Extend Life in Stable Heart Disease

Challenging Longstanding Beliefs Today’s news from the heart research front might set a few cardiology heads spinning. We’ve got big-time findings out of the ISCHEMIA-EXTEND study, throwing more weight on the evidence pile that early invasive heart procedures for patients with stable coronary artery disease don’t actually extend your life. Managing care with a blend...

Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

NatGold Pulling NATG From MEXC Amid Security Concerns

NatGold Digital's sudden decision to yank its NATG token off MEXC Global reeks of regulatory urgency. With the U.S. Treasury clamping down on fund transfers wrapping up MEXC in their action against Russian laundering, NatGold didn't wait for the ink to dry on that order. They’re off the exchange posthaste. A bit of foresight or sheer necessity? Well, it's got the market...

J&J's New Study: Sjögren’s Solution Insight Sparks Debate

Patient-Centric Take on Sjögren's Disease Johnson & Johnson has dropped fresh Phase 2 results on nipocalimab, reminding everyone they're at the helm of reshaping treatments for Sjögren's disease (SjD). A condition leaving about four million folks craving better days, in multiple ways, shines a light on what's gripping patients the hardest. It's hard not to sit up and...

FuelCell Faces Class Action Crunch as Deadline Looms

FuelCell's Legal Storm: What to Know Now You ever get that feeling when your gut knows it all before you even finish reading the headline? Well, buckle up, because FuelCell Energy, Inc. (NASDAQ:FCEL) is staring down a potential class-action train wreck, and they ain't got much track left to skid on before the deadline hits hard on November 10th, 2026. The Crunchy Details...

Johnson & Johnson Unveils Promising PsA Treatment Data

A Game-Changer in Psoriatic Arthritis Treatment? Johnson & Johnson just tossed a headline-grabbing bone into the world of psoriatic arthritis with their new ICOTYDE results. For anyone tangled in the chronic web of psoriatic arthritis, hearing about a potential new treatment like ICOTYDE comes with cautious hope. Between stiff joints and rashy skin, sufferers are often...

Evaluating GLP-1 Telehealth? Key Questions to Consider

Navigating the Landscape of GLP-1 Telehealth Providers In the sprawling jungle of telehealth options for GLP-1 care, it's easy to feel like you're drowning in sameness. Picture this: you land on a sleek page promising the moon and stars, but who knows what's behind the curtain? That's where seasoned advice comes in, like a compass in this murky digital forest. Meant, a...

ecozy's Brezzano Switch: Brewing Simplicity at Home

Breathe the aroma, sip the innovation. ecozy just threw their Brezzano Switch into the arena, and here's the deal: it's a no-nonsense, get-your-caffeine-fix kind of machine aimed at making your mornings simple without compromising on flavor. Unique Features of the Brezzano Switch So, what's cooking? Get this—it's not just any coffee contraption. Built sleek and compact,...

Historic Records Set at 2026 CNO Monumental Marathon

Race to Remember: Monumental Breakthroughs In the chilly November air of Indianapolis, the 2026 CNO Financial Indianapolis Monumental Marathon wasn't just another tick on the calendar—this was a banner day for running. With record-breaking performances across every distance, we saw what happens when a community of athletes, sponsors, and volunteers hits a perfect...

Aurora Innovation Faces Legal Heat Amid Delays

Production Snags at Aurora Innovation Ah, investing – not for the faint-hearted. One day you're riding high, the next you're scraping by, and Aurora Innovation's (NASDAQ:AUR) investors just hit a rough patch. The autonomous trucking darling announced unexpected delays in its delivery schedule, sending shockwaves through its stock price and shaking investor confidence....